ChemoCentryx Soars Most Since 2019 on Autoimmune Drug Approval – Bloomberg.com

ChemoCentryx Soars Most Since 2019 on Autoimmune Drug Approval – Bloomberg.com

The stock has seven buy ratings, one hold and one sell, and an average 12-month price target of $44, according to data compiled by Bloomberg.
See Original Article

Huizenga bill ultimately dissolves the Public Company Accounting Oversight Board – Ripon Advance

“The Streamlining Public Company Accounting Oversight Act will eliminate bureaucracy, make government more efficient by eliminating redundancy,
See Original Article

Elizabeth Warren Shocked to Learn Big Public Accounting Firms Do Shady Sh*t – Going Concern

A senior executive at another major accounting firm, RSM, took a top job at Treasury, where his office expanded a tax break in ways sought by RSM; he then
See Original Article

NYC Overhauls Gifted Programs to Counter School Segregation – Bloomberg.com

New York City said on Friday it will end its highly selective gifted-and-talented education program. The move marks a major policy shift by Mayor Bill de
See Original Article

Taiwan Exports Surge to Record, Defying Predictions of Slowdown – Bloomberg

That compares to a median estimate of 25% in a Bloomberg survey of economists. Imports surged 40.4% to $33.2 billion, the second highest reading on record.
See Original Article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.